Form 4: Bionano Genomics Chief Medical Officer Reports Share Withholding for Tax Obligations

Alka Chaubey, Chief Medical Officer of Bionano Genomics, reports the withholding of 3,075 shares to cover tax obligations related to a vested RSU award.

Summary

• On September 11, 2024, Alka Chaubey, the Chief Medical Officer of Bionano Genomics, had 3,075 shares of common stock withheld by the issuer to satisfy tax obligations.
• These shares were related to a Restricted Stock Unit (RSU) award granted on September 11, 2023, that vested on the transaction date.
• The price per share for the withholding was $0.48.
• Following the transaction, Chaubey beneficially owns 45,323 shares of Bionano Genomics, which includes 153 shares acquired through the Employee Stock Purchase Plan on June 10, 2024.

Sentiment

Score: 5

Explanation: This is a neutral filing related to standard tax withholding procedures, and doesn't inherently indicate positive or negative sentiment.

Industry Context

This filing is a routine disclosure related to insider transactions and is required by the SEC to ensure transparency in the market. It reflects standard compensation practices involving stock-based awards.

Stakeholder Impact

• The transaction has a minor impact on shareholders as it involves the withholding of shares for tax purposes, which is a common practice.
• Employees are affected as it relates to the vesting of their stock-based compensation.

Key Dates

Keywords

Bionano Genomics, BNGO, Form 4, Insider Trading, Alka Chaubey, Chief Medical Officer, RSU, Stock Withholding, Tax Obligations, Employee Stock Purchase Plan